In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment

Journal of Diabetes Science and Technology

Volumn 6, Issue 3, 2012, Pages 634-640

  Pscherer, Stefan ^a   Larbig, Martin ^b   Von Stritsky, Berndt ^b   Pfützner, Andreas ^c   Forst, Thomas ^c,d  

^a Klinikum Traunstein   (Germany)

^b Sanofi   (Germany)

^c Institute for Clinical Research and Development   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Insulin glargine; Postprandial proinsulin; Sulfonylureas

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN GLARGINE; METFORMIN; PROINSULIN; SULFONYLUREA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLARGINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DRUG EFFECT; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; TIME; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; POSTPRANDIAL PERIOD; PROINSULIN; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871542926     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600318     Document Type: Article

References (29)

1. Pfützner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004;27(3):682-7. (Pubitemid 38280533)
2. Røder ME, Dinesen B, Hartling SG, Houssa P, Vestergaard H, Sodoyez-Gofaux F, Binder C. Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care.1999;22(4):609- 14. (Pubitemid 29153049)
3. Uchizono Y, Alarcón C, Wicksteed BL, Marsh BJ, Rhodes CJ. The balance between proinsulin biosynthesis and insulin secretion: where can imbalance lead? Diabetes Obes Metab. 2007; 9 Suppl 2:56-66. (Pubitemid 47543127)
4. Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ; Hoorn Study. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care. 2005;28(4):860-5. (Pubitemid 40434486)
5. Lindahl B, Dinesen B, Eliasson M, Røder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke. 2000;31(12):2936-41.
6. Oh JY, Barrett-Connor E, Wedick NM. Sex differences in the association between proinsulin and intact insulin with coronary heart disease in nondiabetic older adults: the Rancho Bernardo Study. Circulation. 2002;105(11):1311-6. (Pubitemid 34260421)
7. Wohlin M, Sundström J, Arnlöv J, Andrén B, Zethelius B, Lind L. Impaired insulin sensitivity is an independent predictor of common carotid intima-media thickness in a population sample of elderly men. Atherosclerosis. 2003;170(1):181-5. (Pubitemid 37083578)
8. Yudkin JS, May M, Elwood P, Yarnell JW, Greenwood R, Davey Smith G; Caerphilly Study. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia. 2002;45(3):327-36. (Pubitemid 34267354)
9. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an independent predictor of coronary heart disease: report from a 27-year follow-up study. Circulation. 2002;105(18):2153-8. (Pubitemid 34517158)
10. Zethelius B, Lithell H, Hales CN, Berne C. Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp. Diabetologia. 2005;48(5):862-7. (Pubitemid 40767978)
11. Inoguchi T, Umeda F, Kakimoto M, Sako Y, Ishii H, Noda K, Kunisaki M, Imamura M, Yu HY, Etoh T, Yoshikawa H, Aoki T, Hashimoto T, Nawata H. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J. 2000;47(6):763-70. (Pubitemid 32118490)
12. Forst T, Larbig M, Hohberg C, Sorst S, Diessel S, Borchert M, Roth W, Pfützner A. Adding insulin glargine vs. NPH insulin to metformin results in a more eficient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab. 2010;12(5):437-41.
13. Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab. 2008;10(10):931-8.
14. Kirchhof K, Machicao F, Haupt A, Schäfer SA, Tschritter O, Staiger H, Stefan N, Häring HU, Fritsche A. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia. 2008;51(4):597-601.
15. Fritsche A, Madaus A, Stefan N, Tschritter O, Maerker E, Teigeler A, Häring H, Stumvoll M. Relationships among age, proinsulin conversion, and beta-cell function in nondiabetic humans. Diabetes. 2002;51 Suppl 1:S234-9. (Pubitemid 34761521)
16. Jia EZ, Yang ZJ, Zhu TB, Wang LS, Chen B, Cao KJ, Huang J, Ma WZ. Proinsulin is an independent predictor of the angiographical characteristics of coronary atherosclerosis. Cardiology. 2008;110(2):106-11. (Pubitemid 351630035)
17. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care. 1992;15(5):666-92.
18. Lindahl B, Dinesen B, Eliasson M, Røder M, Jansson JH, Huhtasaari F, Hallmans G. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism. 1999;48(9):1197-202. (Pubitemid 29418294)
19. Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138(12):952-9.
20. Larsson H, Ahrén B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab. 1999;84(6):2068-74. (Pubitemid 30647035)
21. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C, Hanefeld M. Efect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism. 2007;56(4):491-6. (Pubitemid 46437254)
22. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation. 1994;89(1):321-30. (Pubitemid 24026506)
23. Festa A, D'Agostino R Jr, Mykkänen L, Tracy RP, Zaccaro DJ, Hales CN, Hafner SM. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with diferent states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19(3):562-8. (Pubitemid 29135156)
24. Lyon CJ, Hsueh WA. Efect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med. 2003;115 Suppl 8A:62S-68S.
25. Nordt TK, Bode C, Sobel BE. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor type I by proinsulin. Diabetologia. 2001;44(9):1121-4. (Pubitemid 32835504)
26. Hohberg C, Forst T, Larbig M, Safinowski M, Diessel S, Hehenwarter S, Weber MM, Schöndorf T, Pfützner A. Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state. Diabetes Care. 2008;31(5):1021-5.
27. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med. 1993;10(1):27-32. (Pubitemid 23089100)
28. Pfützner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T. The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective efect in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2006;8(3):375-84. (Pubitemid 46100531)
29. Stumvoll M, Fritsche A, Stefan N, Hardt E, Häring H. Evidence against a rate-limiting role of proinsulin processing for maximal insulin secretion in subjects with impaired glucose tolerance and beta-cell dysfunction. J Clin Endocrinol Metab. 2001;86(3):1235-9. (Pubitemid 32323010)